LEADER 03156nam 22006495 450 001 996309096403316 005 20240424230152.0 010 $a1-306-77935-9 024 7 $a10.1524/9783486594669 035 $a(CKB)3230000000000410 035 $a(EBL)1348157 035 $a(SSID)ssj0001294277 035 $a(PQKBManifestationID)11777500 035 $a(PQKBTitleCode)TC0001294277 035 $a(PQKBWorkID)11316042 035 $a(PQKB)10709033 035 $a(MiAaPQ)EBC1348157 035 $a(DE-B1597)233578 035 $a(OCoLC)979738281 035 $a(OCoLC)984650634 035 $a(OCoLC)987953053 035 $a(OCoLC)992507852 035 $a(OCoLC)999372612 035 $a(DE-B1597)9783486594669 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/62402 035 $a(EXLCZ)993230000000000410 100 $a20190708d2009 fg 101 0 $ager 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aVon der Deutschen Akademie zum Goethe-Institut $eSprach- und auswärtige Kulturpolitik 1923-1960 /$fEckard Michels 205 $a1st ed. 210 $cDe Gruyter$d2005 210 1$aBerlin ;$aBoston :$cOldenbourg Wissenschaftsverlag,$d[2009] 210 4$d©2005 215 $a1 online resource (267 p.) 225 1 $aStudien zur Zeitgeschichte ;$v70 300 $aDescription based upon print version of record. 311 $a3-486-57807-3 311 $a3-486-59466-4 320 $aIncludes bibliographical references. 327 $tFront Matter --$tDie Gründung der Deutschen Akademie (1923-1925) --$tArbeitsaufnahme im Zeichen der latenten Krise (1925-1929) --$tAuf der Suche nach einem Profil (1927-1932) --$tBeginn und Ausbau der Spracharbeit im In- und Ausland (1930-1939) --$tÜbersteigerte Erwartungen (1933-1939) --$tSprachpolitik und Propaganda im Zeichen der militärischen und finanziellen Expansion (1939-1945) --$tVon der Deutschen Akademie zum Goethe-Institut (1945-1960) --$tBack Matter 330 $aUrspru?nglich auch als Wissenschaftsakademie gedacht, entwickelte sich die Deutsche Akademie in den dreißiger Jahren zur Pionierorganisation fu?r die Verbreitung der deutschen Sprache im Ausland. Ihren gro?ßten Expansionsschub erhielt sie im Zweiten Weltkrieg, als das NS-Regime im Gefolge der Siege der Wehrmacht Deutsch zur fu?hrenden Weltsprache machen wollte. Die 1945 von der US-Besatzungsmacht aufgelo?ste Institution wurde ab 1951 als Goethe-Institut durch die Initiative ihres fru?heren Generalsekreta?rs Franz Thierfelder wieder aufgebaut. Eckard Michels untersucht erstmals die Kontinuita?ten und D 410 0$aStudien zur Zeitgeschichte (Institut fu?r Zeitgeschichte (Munich, Germany)) ;$vBd. 70. 606 $aLearned institutions and societies$zGermany$xHistory 615 0$aLearned institutions and societies$xHistory. 676 $a063.36 686 $aMK 8100$2rvk 700 $aMichels$b Eckard$0929323 801 0$bDE-B1597 801 1$bDE-B1597 906 $aBOOK 912 $a996309096403316 996 $aVon der Deutschen Akademie zum Goethe-Institut$92088682 997 $aUNISA LEADER 04443nam 2200469z- 450 001 9910227346103321 005 20210211 035 $a(CKB)4100000000883872 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/42247 035 $a(oapen)doab42247 035 $a(EXLCZ)994100000000883872 100 $a20202102d2017 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aBiomarkers in Drug Hypersensitivity 210 $cFrontiers Media SA$d2017 215 $a1 online resource (104 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88945-226-3 330 $aBiomarkers, especially those based on pharmacogenomics testing, have proved to be extremely useful for type A adverse drug reactions. Clinical practice guidelines based on biomarker testing are presently being developed and updated for type A adverse drug reactions. In contrast, little attention has been paid to the potential use of biomarkers in type B adverse reactions, characterized by the occurrence of reactions not directly related to the pharmacological properties of the drug. Drug-induced hypersensitivity belongs to those type B reactions. Drug-induced hypersensitivity reactions involve complex mechanisms that include, among others, the metabolic activation and haptenization of drug metabolites. Hence, factors that influence the pharmacokinetics of drug and metabolites may contribute to the development of some drug-induced hypersensitivity reactions. This implies that processes such as ADME (absorption, distribution, metabolism and excretion) that are typically involved in type A adverse drug reactions, may have a role in hypersensitivity reactions too. In addition to metabolic activation, several signal transduction pathways participate and modulate the development and the clinical presentation of drug hypersensitivity. The diverse mechanisms underlying such drug-hypersensitivity reactions lead to four major groups of reactions according to the Gell and Coombs classification: immediate, cytotoxic, immune complex and delayed. The enormous complexity of drug-hypersensitivity reactions is a consequence of the variety of mechanisms involved, which may be related, among others, to drug metabolism, generation of antigenic signals, stimulation and maturation of dendritic cells, presentation of haptens and mechanisms of cytotoxicity. In addition, a plethora of possible clinical presentations exists, including urticaria, angioedema, anaphylaxis, cytopenias, nephritis, serum sickness, vasculitis, contact dermatitis, drug rash, eosinophilia and systemic symptoms, Stevens-Johnson syndrome, toxic epidermal necrolysis and acute generalized exanthematous pustulosis. The rapid progress in the field in recent years indicates that the combination of several disciplines is essential to understand the mechanisms involved in this particular, and not completely understood, type of adverse drug reactions. The objective of this Research Topic is to present insights obtained from both basic and clinical scientists, which may include studies related to the identification, validation, refinement and clinical implementation of biomarkers for drug-induced hypersensitivity. The Topic aims to include recent findings related, but not limited to, potential phenomic, genomic, proteomic, metabolomic and signal transduction biomarkers. These biomarkers could eventually be used in clinical practice and/or these might contribute, as a proof of concept, to our understanding of the complex events leading to drug hypersensitivity reactions. In addition the Topic will cover recent developments and methodological advances in the diagnosis, prevention and therapeutic management of drug-induced hypersensitivity. 606 $aPharmacology$2bicssc 610 $abiomarkers 610 $adrug 610 $adrug metabolism 610 $agenotyping 610 $ahaptenization 610 $ahypersensitivity 610 $amodels 610 $aphenotyping 615 7$aPharmacology 700 $aEmanuela Corsini$4auth$01312093 702 $aSilvia Selinski$4auth 702 $aJose A. G. Agundez$4auth 702 $aElena Garcia-Martin$4auth 702 $aKlaus Golka$4auth 906 $aBOOK 912 $a9910227346103321 996 $aBiomarkers in Drug Hypersensitivity$93030677 997 $aUNINA